Risk factors related to gastrointestinal stromal tumor recurrence after discontinuing postoperative adjuvant imatinib treatment
10.3760/cma.j.issn.1007-631X.2016.02.006
- VernacularTitle:胃肠道间质瘤术后伊马替尼辅助治疗停药后复发的危险因素分析
- Author:
Jia XU
;
Wenyi ZHAO
;
Chun ZHUANG
;
Ming WANG
;
Zizheng ZHANG
;
Gang ZHAO
;
Hui CAO
- Publication Type:Journal Article
- Keywords:
Gastrointestinal stromal tumors;
Chemoradiotherapy,adjuvant;
Relapse
- From:
Chinese Journal of General Surgery
2016;31(2):104-107
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the risk factors related to recurrence of gastrointestinal stromal tumor (GIST) after discontinuing postoperative adjuvant imatinib mesylate (IM) treatment.Methods We retrospectively analyzed our clinical database of 138 GIST patients who received radical resection and subsequent IM adjuvant treatment at the Renji Hospital,Shanghai Jiaotong University School of Medicine between January 2006 and January 2014.Results For the entire Multivariate analysis study group,the overall 5-year recurrent free survival (RFS) rate was 54.5％.There were two tumor characteristics which were independent prognostic factors of GIST treated by postoperative IM:Ki67 index (P =0.005),and serosal invasion (P =0.026).The accuracy of comprehensive evaluation based on the two weighted variables was better than NIH staging criteria(AUC:0.714 vs.0.631).Furthermore,two risk groups were created according to the risk model with 5-year RFS of 81.3％ and 31.1％ as low-risk and high-risk groups,respectively (P ＜0.05).Conclusions For patients with intermediate or high risk in NIH classification,if there was tumor serosal invasion,or if there was no local invasion but Ki67 index ＞ 8％,extended continuous IM adjuvant treatment should be recommended after the primary tumor was radically resected.
